Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. It operates under the Beyond Air and Beyond Cancer segments. The firm developed the LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. The company was founded in 2011 and is headquartered in Garden City, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

XAIR reports successful Q1 launch of LungFit PH, faces revenue challenges

XAIR's Q1 2023 performance reflects initial investment in commercial launch and R&D, with a focus on sustainable growth. The company's successful commercial launch of LungFit PH and plans for expansion demonstrate market potential. However, managing revenue expectations and strategic resource allocation present challenges. Anticipated international market expansion and the potential impact of the autism program offer future opportunities.

Beyond Air reports Q2 earnings, anticipates regulatory progress and challenges

Beyond Air's Q2 earnings call highlighted the commercial progress of LungFit PH, financial results, and strategic plans. The company faces challenges with reimbursement and contract signings but sees opportunities in VCAP trials and regulatory discussions.

XAIR anticipates strong revenue growth and market expansion opportunities

Beyond Air Inc's Q3 2023 performance reflected increased expenses and a GAAP net loss, with a focus on product development and market expansion.
Strengths include positive feedback on LungFit PH, strong leadership, and a dedicated commercial team driving successful launches.
Challenges include regulatory delays, hospital contracting issues, and delays in patient studies, requiring strategic resolutions.
Opportunities lie in team expansion, addressing contracting challenges, FDA meetings, and providing guidance for future growth.
headline

Beyond Air Inc reports successful product launch and secures funding

Beyond Air Inc's Q4 2023 earnings call highlighted a successful commercial launch of LungFit PH and debt financing to support growth initiatives.
While facing challenges such as $0 revenue and cash usage, the company aims to optimize operations and drive revenue generation.
Opportunities lie in expanding product offerings, enhancing customer service, and leveraging unique programs like the early-stage autism initiative.
Overall, Beyond Air Inc remains focused on driving commercial success and maintaining a strong market position through strategic initiatives.

Beyond Air Inc reports Q1 revenue growth and strategic financing

Beyond Air Inc's Q1 2024 earnings call highlighted revenue generation, increased expenses, and strategic financing. The company faces challenges in study endpoints and FDA agreements but sees opportunities in product expansions and regulatory approvals.

Beyond Air Inc reports Q2 earnings, eyes growth opportunities

Beyond Air Inc's Q2 2024 earnings call highlighted revenue guidance for FY 2025, strategic partnerships, and progress in research and development across multiple therapeutic areas.
The company's commercial success with LungFit PH, FDA approvals, and ongoing studies demonstrate a commitment to innovation and market growth amidst financial challenges.
Challenges in financial performance, market dynamics, and competition underscore the need for continued strategic planning and operational efficiency to drive sustainable profitability.
With a diversified pipeline, upcoming data releases, and product enhancements, Beyond Air Inc is poised to capitalize on growth opportunities and strengthen its position in the market.

Beyond Air Inc reports revenue growth and regulatory milestones ahead

Beyond Air Inc shows promising revenue growth and market acceptance, supported by new contracts and product demand.
While facing financial losses and regulatory uncertainties, the company's focus on innovation and customer relationships positions it well for future success.
Anticipated FDA decisions, ongoing hospital starts, and strong leadership underpin the company's growth potential and strategic outlook.

Beyond Air Q4: Growth Amid Challenges, Revenue Down

Beyond Air Inc. concluded fiscal Q4 2024 with significant developments and challenges. While the company demonstrated strong product usage and customer retention, it faces hurdles in customer acquisition speed and legal issues. Financially, the substantial net loss and revised down revenue projections highlight areas needing attention.

Beyond Air Inc reports growth in hospital clients and global expansion

Beyond Air Inc's Q2 2025 earnings call highlighted significant achievements, including a surge in hospital clients, strategic partnerships for global expansion, and progress on regulatory approvals for key products. The company showcased a commitment to financial sustainability through cash runway extension and cost reduction measures.
While facing challenges such as regulatory approval delays and a reported net loss, Beyond Air Inc remains focused on innovation and market growth. Opportunities lie in leveraging partnerships, product expansions, and cash reserves to drive future revenue and profitability.
Overall, Beyond Air Inc's performance reflects a mix of strengths, challenges, and opportunities, positioning the company for potential growth and market success. Analyst inquiries during the call underscored a keen interest in contract growth, strategic partnerships, and revenue prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

Beyond Air CEO Steven Lisi recently bought the dip in XAIR stock, increasing his stake by ~4%. I see no attempt in Mr. Lisi's actions to artificially pump the stock to sell his stake at a higher price - I explain why.

Beyond Air: Follow The CEO And Buy The Dip

Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.

Implied Volatility Surging for Beyond Air (XAIR) Stock Options

The stock price of Beyond Air Inc (NASDAQ: XAIR) fell by over 30% this past week. This is why it happened.

Beyond Air Stock (XAIR): Why The Price Fell This Week

Beyond Air Inc (NASDAQ: XAIR) expects a delay in FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn. Based on ongoing communications with the FDA, the company no longer believes that the U.S. commercial launch of LungFit PH will take place before December 31, 2021.

Beyond Air Shares Fall As US Launch Of LungFit PH Not Expected In 2021

A regulatory delay is weighing heavily on the medical device company's shares today.

Why Beyond Air Stock Is Tanking Today

Fulgent Genetics

Ocugen, Inc.

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

3 Small-Cap COVID Stocks With Huge Upside

Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the maximum allowable allotment of committed capital Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the maximum allowable allotment of committed capital

Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement

The stock price of Beyond Air Inc (NASDAQ: XAIR) increased 21.82% today. This is why it happened.

Beyond Air (XAIR) Stock: Why The Price Surged Today

Beyond Air, Inc.'s (XAIR) CEO Steve Lisi on Q2 2022 Results - Earnings Call Transcript

U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quarter of calendar year 2021

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

GARDEN CITY, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 30 – December 2, 2021. Beyond Air will provide a pre-recorded investor presentation and will be available for virtual one-on-one meetings during the conference.

Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time

Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast

Beyond Air Inc (NASDAQ: XAIR) has announced interim data from Australia's ongoing LungFit GO pilot study.  Related:   Beyond Air Issues Regulatory Update For LungFit PH System.

Beyond Air Reports Interim Data Of Self-Administered Inhaled NO For Lung Disease

Beyond Air Inc (NASDAQ: XAIR) announced a regulatory update for the approval process of its LungFit PH system. The Company said that the FDA facility inspections are currently ongoing.

Beyond Air Issues Regulatory Update For LungFit PH System

FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval

Beyond Air® Provides Global Regulatory Update for LungFit® PH

GARDEN CITY, N.Y., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th to 23rd.

Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities.

Beyond Air® Announces CFO Transition

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2022 Results - Earnings Call Transcript

Shares of Beyond Air (NASDAQ:XAIR) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 22.50% year over year to ($0.31), which missed the estimate of ($0.21).

Beyond Air: Q1 Earnings Insights

U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calendar year 2021

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022

Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know

Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time

News for Beyond Air Inc Stock (XAIR)